Tom Powles/bartscancer.london
Aug 26, 2024, 20:08
Tom Powles: Belzutifan significantly outperformed Everolimus in heavily pretreated clear cell renal cancer
Tom Powles, Professor of urology cancer at the University of London and the Director of Barts Cancer Centre, shared a post on X:
“Belzutifan significantly outperformed everolimus in heavily pretreated clear cell renal cancer.
Respiratory Rate, Progression-free survival , Quality of life but no Oculus Sinister. Data suggests belzutifan is better in less heavily treated disease and in combination. 1st line and adjuvant trials awaited.”
Source: Tom Powles/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 22, 2025, 05:18
Feb 22, 2025, 05:15
Feb 22, 2025, 05:05
Feb 22, 2025, 04:54
Feb 22, 2025, 04:49
Feb 22, 2025, 04:33
Feb 22, 2025, 04:29